Showing 621 - 640 results of 228,752 for search '(( 5 ((non decrease) OR (mean decrease)) ) OR ( 10 ((ng decrease) OR (a decrease)) ))', query time: 1.58s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627
  8. 628

    FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) HuH6 cells (2.5 x 10<sup>6</sup> cells in 25% Matrigel) were injected subcutaneously into the right flank of 6-week-old female athymic nude mice. …”
  9. 629

    APB5, but not APA5, decreases apoptosis in alveolar epithelial cells in lungs of BLM-treated mice. by Masami Kishi (6167105)

    Published 2018
    “…The administration of APA5 did not change the number of TUNEL-positive cells from that in BLM-treated mice, whereas that of APB5 significantly decreased them. …”
  10. 630
  11. 631
  12. 632

    S1 Data - by Francois Kiemde (5369657)

    Published 2024
    “…A The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) was also reported.…”
  13. 633

    Characteristic of study population. by Francois Kiemde (5369657)

    Published 2024
    “…A The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) was also reported.…”
  14. 634
  15. 635
  16. 636

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  17. 637
  18. 638
  19. 639
  20. 640